Fractyl Labs Launches Pivotal Revita Diabetes Device Trial

First Patients Enrolled in Multicenter Clinical Trial of Fractyl Revita DMR System

WALTHAM, Mass.--()--Fractyl Laboratories Inc. (Fractyl) today announced that patient enrollment has begun in a multicenter clinical trial (“Revita-1” trial) being conducted in Europe and South America to evaluate the safety and performance of the Revita™ Duodenal Mucosal Resurfacing™ (DMR) System. Revita is the first non-invasive, implant free duodenal resurfacing procedural therapy designed to directly treat the digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes.

“The Revita-1 study will expand our understanding of the safety and efficacy of the Revita DMR procedure in patients with type 2 diabetes,” said Harith Rajagopalan, MD, PhD, Co-Founder and CEO of Fractyl. “It will also guide our plans for multi-arm pivotal trials, along with data from our earlier, proof-of-concept human studies that we plan to publish this year.”

More than ten patients have been treated in the first phase of the Revita-1 study, which will enroll 50 patients across ten international sites. The primary efficacy endpoint is change in HbA1c in patients with uncontrolled type 2 diabetes, defined as having poor glucose control on oral medications and an HbA1c of 7.5 to 10 percent. The second phase of the study, a double-blinded, sham-controlled trial that will enroll up to 240 patients, will begin in 2016.

“My center has now treated four patients in the Revita 1 trial, and two patients have crossed the one-month threshold and appear to be well satisfied with this minimally invasive procedure,” said Geltrude Mingrone, MD, PhD. “We have known for some time that bariatric surgeries can improve glycemic control independent of weight loss; it will be interesting to see if Revita can offer a safe, less invasive option with similar metabolic benefits.”

About Fractyl and the Revita™ Duodenal Mucosal Resurfacing (DMR) System

Fractyl Laboratories Inc., a private company based in Waltham, MA, was founded with the mission to change the treatment of type 2 diabetes. Fractyl has developed a minimally invasive, device-based, implant-free duodenal mucosal resurfacing procedure (Revita DMR) that directly addresses the intestinal hormonal impairment that contributes to insulin resistance and changes how the body absorbs and processes sugar. Fractyl is currently engaged in clinical trials designed to demonstrate that the Revita DMR procedure can dramatically improve glucose control and potentially reduce the need for additional medications in type 2 diabetes. For more information, visit or


Fractyl Laboratories Inc.
Russell LaMontagne, 917-744-7957

Help employers find you! Check out all the jobs and post your resume.

Back to news